Lemaitre Vascular (LMAT) EBITDA Margin (2010 - 2026)
Lemaitre Vascular's (LMAT) quarterly EBITDA Margin came in at 28.98% in Q2 2026, up 385.0% year-over-year from 5.98% in Q2 2025, and up 8.52% quarter-over-quarter from 26.71% in Q1 2026.
Powered by 
Analysis
Lemaitre Vascular (LMAT) EBITDA Margin (2010 - 2026) Analysis & Trends
Lemaitre Vascular (LMAT) has reported EBITDA Margin for 17 consecutive years, with 28.98% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA Margin rose 385.0% year-over-year to 28.98% in Q2 2026; TTM through Jun 2026 was 29.46%, a 612.0% increase from a year earlier, with the FY2025 full-year figure at 27.21%, up 344.0% from the prior year.
- EBITDA Margin was 28.98% for Q2 2026 at Lemaitre Vascular, up from 26.71% in the prior quarter.
- Over five years, EBITDA Margin peaked at 33.27% in Q3 2025 and troughed at 13.74% in Q2 2022.
- A 5-year average of 22.32% and a median of 21.65% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin plunged 1357 bps in 2022 and jumped 929 bps in 2025, its largest moves.
- Over 5 years, EBITDA Margin stood at 17.01% in 2022, then increased by 23 bps to 20.88% in 2023, then grew by 10 bps to 23.07% in 2024, then rose by 27 bps to 29.22% in 2025, then fell by 1 bps to 28.98% in 2026.
- The last three EBITDA Margin figures came in at 28.98% (Q2 2026), 26.71% (Q1 2026), and 29.22% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 24.33% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 19.15% |
| 10 | Lemaitre Vascular | 1.80 Bn | 1.43 Bn | 50.76 Mn | 28.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.98% |
| Mar 31, 2026 | 26.71% |
| Dec 31, 2025 | 29.22% |
| Sep 30, 2025 | 33.27% |
| Jun 30, 2025 | 25.13% |
| Mar 31, 2025 | 21.09% |
| Dec 31, 2024 | 23.07% |
| Sep 30, 2024 | 23.98% |
| Jun 30, 2024 | 25.75% |
| Mar 31, 2024 | 22.20% |
| Dec 31, 2023 | 20.88% |
| Sep 30, 2023 | 19.36% |
| Jun 30, 2023 | 18.86% |
| Mar 31, 2023 | 16.73% |
| Dec 31, 2022 | 17.01% |
| Sep 30, 2022 | 15.76% |
| Jun 30, 2022 | 13.74% |
| Mar 31, 2022 | 20.04% |
| Dec 31, 2021 | 21.01% |
| Sep 30, 2021 | 23.65% |